Dr S Rafla (Manitoba Cancer Treatment and Research Foundation, Winnipeg General Hospital, Winnipeg, Canada) This paper reviews 407 cases of mucous and salivary gland tumours, treated in the Royal Marsden Hospital, London. The majority of these patients were under the care of Dr M Lederman, and I am grateful to him for permitting me to report on them.
Cases originating in major salivary glands numbered 268 and the rest occurred in ectopic sites mostly in the upper air and food passages.
Pleomorphic adenomas (172 cases) were treated mostly with enucleation and radiotherapy. Spillage of the tumour during enucleation was reported in 14 cases. In a follow-up period of five to fifteen years, only 6 cases recurred (3 5 %). The response of pleomorphic adenoma to radiotherapy was assessed in 60 cases. While 10% of parotid tumours disappeared under radiotherapy, one-third of tumours in ectopic sites did the same. The results of this method of treatment seem to compare favourably with more radical methods, e.g. parotidectomy.
The different malignant forms comprise 179 cases: cylindromas 54, adenocarcinomas 71, and 54 distributed among less common types like malignant mixed tumours and mucoepidermoids. The treatment of malignant tumours was essentially a combination of surgerymostly excisionand radiotherapy. In this context excision means removal of the portion of the gland containing tumour. However, 81 cases were treated with radiotherapy alone either because the case was deemed inoperable or because it disappeared completely under radiotherapy which was used as the primary method of treatment due to unfavourable features, e.g. skin involvement or deep fixation.
Of 99 cases 30 (30%) were alive and well after five years while only 6 out of 37 (160%) survived for ten years. These bad results are unfortunately in agreement with other series even when more radical methods were applied.
Nerve involvement by disease, a finding not reported in any of the 172 pleomorphic adenomas, was noted in 29 of the malignant tumours. This finding is of serious significance; about half the 29 patients continued to have persistent disease after treatment and none remained alive and free of disease for five years.
Lymphatic metastases were noticed in about one-quarter of the patients, whose prognosis depended on the stage of nodal involvement. Where the nodes were deeply fixed or where contralateral ones were affected, none of the patients lived free of disease for five years. About one-fifth of the patients suffered from distant metastases. While such patients may live for a relatively long time, this happens only in patients with pulmonary metastases; the longest survival of a patient with bone metastasis was less than two years.
It was possible to assess the response of 67 The role of radiotherapy in the management of these tumours has never been clearly defined. In the past surgery has been regarded as the treatment of choice, with radiotherapy reserved for recurrent or inoperable cases. Such selection has made the assessment of the role of radiotherapy difficult.
